VHIRtv2011.4.13---UCL-ARSeNEL :人工肝

VHIRtv2011.4.13---UCL-ARSeNEL :人工肝
Artificial liver: development of extracorporeal systems to support failing organs
The incidence of liver disease is increasing worldwide and about 1 million patients die from liver failure each year. In liver failure, the accumulation of protein bound toxins and increased susceptibility to infection cause multi-organ failure and death. Apart from liver transplantation, there is no treatment known to prolong the life of these patients. A cost-effective and clinically efficacious 'liver support device' is an unmet clinical need. We have developed and tested a novel 'liver support device' (UCL-ARSeNEL) that could be used on a similar basis to that of a kidney dialysis machine. The concept of the novel device evolved at UCL and is based upon the two discoveries: 1. that albumin, a major molecule involved in the detoxification process, is reduced irreversibly both in concentration and functional capacity (determined using electron paramagnetic resonance spi-label studies) and, 2. that endotoxaemia, which is know to increase as a consequence of liver disease, contributes to increased risk of infection by inappropriately activating the host immune system. The new system device incorporates albumin removal and replacement and, endotoxin removal. The initial studies have provided proof-of concept information, following which we plan to take the project through to a first in man study.

人工肝：体外系统，以支持衰竭器官
肝病的发病率正在上升全球约有100万患者死于肝功能衰竭的一年。在肝功能衰竭，蛋白质结合毒素的积累和对感染的易感性增加导致多器官衰竭和死亡。除了肝移植，但众所周知，延长这些病人没有生命的治疗。一个具有成本效益和临床疗效，人工肝支持装置'是一个未得到满足临床需要。我们已经开发并测试了小说的人工肝支持装置'（伦敦大学学院，ARSeNEL）可在类似基准用于对肾脏透析机。在伦敦大学学院的进化这个新产品的概念，是基于两个发现：1。 ，白蛋白，一个重要的分子解毒过程中所涉及的，是不可逆转的浓度降低和功能的双重身份（确定使用电子顺磁共振spi的标签研究）和，2。是内毒素血症，这是一个知道增加肝脏疾病的后果，有助于增加感染的风险不恰当地激活宿主的免疫系统。采用新的系统设备拆卸和更换和白蛋白，内毒素清除。最初的研究提供了验证的概念的信息后，我们计划采取通过对人的研究第一次在该项目